SubsidieMeestersiLoF: AI-augmented photonics to identify and quantify disease biomarkers
iLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures.
Projectdetails
Introduction
iLoF is a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.
Technology Overview
Through advanced AI and photonics, we collect massive amounts of data to build a digital library of biomarkers and biological profiles. This effort brings together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster.
Data Collection Method
Our platform captures label-free patterns in biological liquid samples to generate specific patient or disease signatures. The iLoF device generates multiple highly focused, non-destructive laser beams that interrogate the biological sample to obtain a digital signal of its light pattern.
Flexibility and Agnosticism
That signal is used to detect modifications, providing a flexible and agnostic tool that is not limited to a single use or disease.
Current Focus
The current project focuses on developing an Alzheimer’s disease (AD) clinical trial patient screening tool.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.495.850 |
| Totale projectbegroting | € 3.565.500 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ILOF - INTELLIGENT LAB ON FIBER, UNIPESSOAL LDApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENTJaxBio aims to revolutionize lung cancer diagnosis and treatment with LUMEN, a non-invasive liquid biopsy assay that detects cancer early and predicts treatment response using advanced DNA-chip technology. | EIC Accelerator | € 2.493.000 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENT
JaxBio aims to revolutionize lung cancer diagnosis and treatment with LUMEN, a non-invasive liquid biopsy assay that detects cancer early and predicts treatment response using advanced DNA-chip technology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer MonitoringDevelop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies. | ERC Proof of... | € 150.000 | 2023 | Details |
A light-efficient microscope for fast volumetric imaging of photon starved samplesLowLiteScope aims to revolutionize bioluminescence microscopy by using AI-driven light field techniques for high-resolution 3D imaging of biological samples, enhancing research capabilities in life sciences. | ERC Proof of... | € 150.000 | 2024 | Details |
FOLLOW: Labelfree Immunoassay Photonic DeviceOntwikkeling van een prototype immunoassay-apparaat voor in vitro detectie van eiwitbiomarkers om terugkeer van kanker te diagnosticeren en ziekteprogressie te monitoren met een druppel biologische vloeistof. | Mkb-innovati... | € 159.425 | 2015 | Details |
Method for Integrated All-Optical Biological Analysis at ScaleDeveloping an all-optical platform for precise optogenetic probing and automated data analysis to enhance research in neuroscience, developmental biology, and cancer. | ERC Proof of... | € 150.000 | 2024 | Details |
Frequency-agile lasers for photonic sensingFORTE aims to develop a scalable, high-performance, photonic integrated circuit-based laser technology for fiber sensing and FMCW LiDAR, enhancing manufacturing and reducing costs. | EIC Transition | € 1.966.218 | 2023 | Details |
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer Monitoring
Develop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies.
A light-efficient microscope for fast volumetric imaging of photon starved samples
LowLiteScope aims to revolutionize bioluminescence microscopy by using AI-driven light field techniques for high-resolution 3D imaging of biological samples, enhancing research capabilities in life sciences.
FOLLOW: Labelfree Immunoassay Photonic Device
Ontwikkeling van een prototype immunoassay-apparaat voor in vitro detectie van eiwitbiomarkers om terugkeer van kanker te diagnosticeren en ziekteprogressie te monitoren met een druppel biologische vloeistof.
Method for Integrated All-Optical Biological Analysis at Scale
Developing an all-optical platform for precise optogenetic probing and automated data analysis to enhance research in neuroscience, developmental biology, and cancer.
Frequency-agile lasers for photonic sensing
FORTE aims to develop a scalable, high-performance, photonic integrated circuit-based laser technology for fiber sensing and FMCW LiDAR, enhancing manufacturing and reducing costs.